5-aminolevulinic acid, a precursor of heme, reduces both fasting and postprandial glucose levels in mildly hyperglycemic subjects

Nutrition

Volumn 29, Issue 7-8, 2013, Pages 1030-1036

  Higashikawa, Fumiko ^a   Noda, Masafumi ^a   Awaya, Tomokazu ^b   Tanaka, Tohru ^c   Sugiyama, Masanori ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c SBI Pharmaceuticals Co   (Japan)

Author keywords

Impaired fasting glucose; Impaired glucose tolerance; Prediabetes; Preventive medicine

Indexed keywords

5 AMINOLEVULINIC ACID PHOSPHATE; ALBUMIN; ANTIDIABETIC AGENT; GLUCOSE; HEMATOLOGIC AGENT; HEMOGLOBIN A1C; PLACEBO; SODIUM FERROUS CITRATE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ALBUMIN BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASTHENOPIA; BILIRUBIN BLOOD LEVEL; BLADDER IRRITATION; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIET RESTRICTION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA; ORAL GLUCOSE TOLERANCE TEST; OTITIS; PAIN; PERIPHERAL EDEMA; POSTPRANDIAL STATE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; SLEEP DISORDER; SODIUM BLOOD LEVEL; STOMATITIS; THROMBOCYTE; TREATMENT DURATION; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; VOMITING;

ADULT; AGED; AMINOLEVULINIC ACID; BLOOD GLUCOSE; DOUBLE-BLIND METHOD; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HEME; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; IRON, DIETARY; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 84878963941     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2013.02.008     Document Type: Article

References (36)

1. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pr 2010, 87:4-14.
2. Nathan D.M., Chew E., Christophi C.A., Davis M.D., Fowler S., Goldstein B.J., et al. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabetic Med 2007, 24:137-144.
3. Ziegler D., Rathmann W., Dickhaus T., Meisinger C., Mielck A. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008, 31:464-469.
4. Morokuma Y., Yamazaki M., Maeda T., Yoshino I., Ishizuka M., Tanaka T., et al. Hair growth stimulatory effect by a combination of 5-aminolevulinic acid and iron ion. Int J Dermatol 2008, 47:1298-1303.
5. Patti M.E., Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 2010, 31:364-395.
6. Sleigh A., Raymond-Barker P., Thackray K., Porter D., Hatunic M., Vottero A., et al. Mitochondrial dysfunction in patients with primary congenital insulin resistance. J Clin Invest 2011, 121:2457-2461.
7. Rossmann-Ringdahl I., Olsson R. Porphyria cutanea tarda in a Swedish population: risk factors and complications. Acta Derm Venereol 2005, 85:337-341.
8. Polo C.F., Vázquez E.S., Gerez E.N., Caballero F.A., Batlle A.M. STZ-induced diabetes in mice and heme pathway enzymes. Effect of allylisopropylacetamide and alpha-tocopherol. Chem Biol Interact 1995, 95:327-334.
9. Kade I.J., Borges V.C., Savegnago L., Ibukun E.O., Zeni G., Nogueira C.W., et al. Effect of oral administration of diphenyl diselenide on antioxidant status, and activity of delta aminolevulinic acid dehydratase and isoforms of lactate dehydrogenase, in streptozotocin-induced diabetic rats. Cell Biol Toxicol 2009, 25:415-424.
10. Schmatz R., Perreira L.B., Stefanello N., Mazzanti C., Spanevello R., Gutierres J., et al. Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats. Biochimie 2012, 94:374-383.
11. Seino Y., Nanjo K., Tajima N., Kadowaki T., Kashiwagi A., Araki E., et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 2010, 1:212-228.
12. Henareh L., Agewall S. 2-h postchallenge plasma glucose predicts cardiovascular events in patients with myocardial infarction without known diabetes mellitus. Cardiovasc Diabetol 2012, 11:93.
13. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924.
14. Liao D., Shofer J.B., Boyko E.J., McNeely M.J., Leonetti D.L., Kahn S.E., et al. Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese-Americans with normal fasting glucose. Diabetes Care 2001, 24:39-44.
15. Koga M., Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J 2010, 57:751-762.
16. Suwa T., Ohta A., Matsui T., Koganei R., Kato H., Kawata T., et al. Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). Endocr J 2010, 57:135-140.
17. Fernández-Real J.M., López-Bermejo A., Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002, 51:2348-2354.
18. Tuomainen T.P., Nyyssönen K., Salonen R., Tervahauta A., Korpela H., Lakka T., et al. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1,013 eastern Finnish men. Diabetes Care 1997, 20:426-428.
19. Jiang R., Manson J.E., Meigs J.B., Ma J., Rifai N., Hu F.B. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004, 291:711-717.
20. Bao W., Rong Y., Rong S., Liu L. Dietary iron intake, body iron stores, and the risk of type 2 diabetes: a systematic review and meta-analysis. BMC Med 2012, 10:119.
21. Jiang R., Ma J., Ascherio A., Stampfer M.J., Willett W.C., Hu F.B. Dietary iron intake and blood donations in relation to risk of type 2 diabetes in men: a prospective cohort study. Am J Clin Nutr 2004, 79:70-75.
22. Luan de C., Li H., Li S.J., Zhao Z., Li X., Liu Z.M. Body iron stores and dietary iron intake in relation to diabetes in adults in North China. Diabetes Care 2008, 31:285-286.
23. Lee D.H., Folsom A.R., Jacobs D.R. Dietary iron intake and Type 2 diabetes incidence in postmenopausal women: the Iowa Women's Health Study. Diabetologia 2004, 47:185-194.
24. Atamna H., Killilea D.W., Killilea A.N., Ames B.N. Heme deficiency may be a factor in the mitochondrial and neuronal decay of aging. Proc Natl Acad Sci U S A 2002, 99:14807-14812.
25. Chernova T., Steinert J.R., Guerin C.J., Nicotera P., Forsythe I.D., Smith A.G. Neurite degeneration induced by heme deficiency mediated via inhibition of NMDA receptor-dependent extracellular signal-regulated kinase 1/2 activation. J Neurosci 2007, 27:8475-8485.
26. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63:1187-1192.
27. Kuusisto J., Koivisto K., Mykkänen L., Helkala E.L., Vanhanen M., Hänninen T., et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 1997, 315:1045-1049.
28. Möbius K., Arias-Cartin R., Breckau D., Hännig A.L., Riedmann K., Biedendieck R., et al. Heme biosynthesis is coupled to electron transport chains for energy generation. Proc Natl Acad Sci U S A 2010, 107:10436-10441.
29. Ogura S., Maruyama K., Hagiya Y., Sugiyama Y., Tsuchiya K., Takahashi K., et al. The effect of 5-aminolevulinic acid on cytochrome c oxidase activity in mouse liver. BMC Res Notes 2011, 4:66.
30. Atamna H., Liu J., Ames B.N. Heme deficiency selectively interrupts assembly of mitochondrial complex IV in human fibroblasts: revelance to aging. JBiol Chem 2001, 276:48410-48416.
31. Gatta L.B., Vitali M., Verardi R., Arosio P., Finazzi D. Inhibition of heme synthesis alters Amyloid Precursor Protein processing. J Neural Transm 2009, 116:79-88.
32. Müller-Höcker J. Cytochrome c oxidase deficient fibres in the limb muscle and diaphragm of man without muscular disease: an age-related alteration. J Neurol Sci 1990, 100:14-21.
33. Castellani R., Hirai K., Aliev G., Drew K.L., Nunomura A., Takeda A., et al. Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res 2002, 70:357-360.
34. Lu H., Koshkin V., Allister E.M., Gyulkhandanyan A.V., Wheeler M.B. Molecular and metabolic evidence for mitochondrial defects associated with beta-cell dysfunction in a mouse model of type 2 diabetes. Diabetes 2010, 59:448-459.
35. Gallardo M.E., Moreno-Loshuertos R., López C., Casqueiro M., Silva J., Bonilla F., et al. m.6267G>A: a recurrent mutation in the human mitochondrial DNA that reduces cytochrome c oxidase activity and is associated with tumors. Hum Mutat 2006, 27:575-582.
36. Xin M.G., Zhang J., Block E.R., Patel J.M. Senescence-enhanced oxidative stress is associated with deficiency of mitochondrial cytochrome c oxidase in vascular endothelial cells. Mech Ageing Dev 2003, 124:911-919.